Proteolysis Laboratory, Molecular Biology Institute of Barcelona, Spanish Research Council (CSIC), Barcelona Science Park, c/Baldiri Reixac, 15-21, 08028 Barcelona, Catalonia, Spain.
University of Louisville School of Dentistry, Louisville, Kentucky 40202.
J Biol Chem. 2013 May 17;288(20):14287-14296. doi: 10.1074/jbc.M112.444927. Epub 2013 Apr 4.
Zymogenicity is a regulatory mechanism that prevents inadequate catalytic activity in the wrong context. It plays a central role in maintaining microbial virulence factors in an inactive form inside the pathogen until secretion. Among these virulence factors is the cysteine peptidase gingipain B (RgpB), which is the major virulence factor secreted by the periodontopathogen Porphyromonas gingivalis that attacks host vasculature and defense proteins. The structure of the complex between soluble mature RgpB, consisting of a catalytic domain and an immunoglobulin superfamily domain, and its 205-residue N-terminal prodomain, the largest structurally characterized to date for a cysteine peptidase, reveals a novel fold for the prodomain that is distantly related to sugar-binding lectins. It attaches laterally to the catalytic domain through a large concave surface. The main determinant for latency is a surface "inhibitory loop," which approaches the active-site cleft of the enzyme on its non-primed side in a substrate-like manner. It inserts an arginine (Arg(126)) into the S1 pocket, thus matching the substrate specificity of the enzyme. Downstream of Arg(126), the polypeptide leaves the cleft, thereby preventing cleavage. Moreover, the carbonyl group of Arg(126) establishes a very strong hydrogen bond with the co-catalytic histidine, His(440), pulling it away from the catalytic cysteine, Cys(473), and toward Glu(381), which probably plays a role in orienting the side chain of His(440) during catalysis. The present results provide the structural determinants of zymogenic inhibition of RgpB by way of a novel inhibitory mechanism for peptidases in general and open the field for the design of novel inhibitory strategies in the treatment of human periodontal disease.
酶原性是一种调节机制,可防止在错误的环境中出现催化活性不足的情况。它在维持微生物毒力因子处于无活性形式方面起着核心作用,这些毒力因子存在于病原体内部,直到分泌。这些毒力因子中包括半胱氨酸蛋白酶gingipain B(RgpB),它是侵袭宿主血管和防御蛋白的牙周病原体牙龈卟啉单胞菌分泌的主要毒力因子。可溶性成熟 RgpB 与 205 个残基 N 端前肽的复合物的结构,该前肽是迄今为止为半胱氨酸蛋白酶鉴定的最大结构,揭示了前肽的一种新型折叠,该折叠与糖结合凝集素的结构远相关。它通过一个大的凹面从侧面附着在催化结构域上。潜伏期的主要决定因素是一个表面“抑制环”,它以类似于底物的方式在非初始侧接近酶的活性位点裂缝。它将精氨酸(Arg(126))插入 S1 口袋,从而匹配酶的底物特异性。在 Arg(126)的下游,多肽离开裂缝,从而阻止切割。此外,Arg(126)的羰基与共催化组氨酸 His(440)建立了非常强的氢键,将其从催化半胱氨酸 Cys(473)中拉走,并朝向 Glu(381),这可能在催化过程中起到定向 His(440)侧链的作用。目前的结果提供了 RgpB 酶原性抑制的结构决定因素,为一般肽酶的新型抑制机制开辟了道路,并为人类牙周病治疗的新型抑制策略的设计开辟了道路。